SCHEMBL697442

SCHEMBL697442

CCc1cc(C(N)=O)c(C)c(CC)c1C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 1/20 0.39
L3MBTL1 Q9Y468 2/20 0.34
POLB P06746 1/20 0.34
PARP1 P09874 2/20 0.33
CDC7 O00311 1/20 0.33
GABRP O00591 1/20 0.33
GABRD O14764 1/20 0.33
GABRA1 P14867 1/20 0.33
GABRB1 P18505 1/20 0.33
GABRG2 P18507 1/20 0.33
GABRB3 P28472 1/20 0.33
GABRA5 P31644 1/20 0.33
GABRA3 P34903 1/20 0.33
GABRA2 P47869 1/20 0.33
GABRB2 P47870 1/20 0.33
GABRA4 P48169 1/20 0.33
GABRE P78334 1/20 0.33
GABRA6 Q16445 1/20 0.33
GABRG1 Q8N1C3 1/20 0.33
GABRG3 Q99928 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3828018 0.85 SMN1; SMN2 (0.39) SMN1; SMN2L3MBTL1POLBPARP1CDC7
SCHEMBL8531143 0.81 SMN1; SMN2 (0.35) SMN1; SMN2L3MBTL1POLBPARP1CDC7
SCHEMBL28393333 0.81 ALDH1A1 (0.37) SMN1; SMN2POLBNNMTALDH1A1KDM4E
SCHEMBL13729466 0.81 SMN1; SMN2 (0.38) SMN1; SMN2POLBNNMTALDH1A1KDM4E
SCHEMBL4951717 0.81 SMN1; SMN2 (0.39) SMN1; SMN2L3MBTL1POLBPARP1CDC7
SCHEMBL3829811 0.81 SLC11A2 (0.38) SMN1; SMN2L3MBTL1POLBPARP1CDC7
SCHEMBL29175226 0.80 SMN1; SMN2 (0.36) SMN1; SMN2L3MBTL1POLBPARP1CDC7
SCHEMBL29175224 0.78 DGAT1 (0.37)
SCHEMBL59737 0.77 NNMT (0.36) SMN1; SMN2PARP1CDC7GABRPGABRD
SCHEMBL474164 0.77 NNMT (0.36) SMN1; SMN2PARP1CDC7GABRPGABRD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-102532020-B 5, 6, or 7-substituted -3-(hetero) arylisoquinolinamine derivatives REXAHN PHARMACEUTICALS INC 2015-02-25 CN disclosed
EP-2423196-A1 5, 6 or 7-substituted-3-phenylisoquinolinamine derivatives and therapeutic use thereof Rexahn Pharmaceuticals, Inc. (US) 2012-02-29 EP disclosed
CN-101573337-A 5, 6 or 7-substituted-3- (hetero) aryl-isoquinolinamine derivatives as antitumor agents REXAHN PHARMACEUTICALS INC (US) 2009-11-04 CN disclosed
EP-2099765-A2 5, 6, OR 7-SUBSTITUTED-3-(HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS Rexahn Pharmaceuticals, Inc. (US) 2009-09-16 EP disclosed
WO-2008063548-A2 5, 6, OR 7-SUBSTITUTED-S- (HETERO)ARYLISOQUINOLINAMINE DERIVATIVES AS ANTITUMOR AGENTS REXAHN PHARMACEUTICALS, INC. (US) 2008-05-29 WO disclosed